https://en.wowtale.net/2025/05/19/231108/

This interview with Peptirna Therapeutics discusses their development of a peptide-based delivery platform for siRNA (small interfering RNA) therapies. The company aims to overcome limitations of existing delivery methods, such as Lipid Nanoparticles (LNPs) and GalNAc, which struggle with delivering drugs to non-liver tissues and endosomal escape within cells. Peptirna's platform utilizes positively charged peptides that bind to negatively charged siRNA, forming nanoparticles for effective cell entry and delivery, and they are also leveraging this technology for a short-term cosmetic ingredient delivery business. The article highlights the company's potential to address unmet needs in the siRNA market and its goal of technology transfer or acquisition by larger pharmaceutical or biotech firms.